CRBN is a key protein regulating fibrosis following GDS. THD exerts anti-fibrotic effects by targeting CRBN and inhibiting the NF-κB pathway. These findings unveil a novel intervention target, CRBN, for attenuating fibrogenesis after GDS.
Wang et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: